A bill to provide that no funds may be expended by the United States Trade Representative to negotiate data exclusivity provisions for certain pharmaceutical products.
Latest action · Oct 8, 2004 Read twice and referred to the Committee on Finance. (text of measure as introduced: CR S10848)
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedOct 8, 2004
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Prohibits funds appropriated or otherwise obligated to the U.S. Trade Representative from being expended to negotiate data exclusivity provisions with any country with respect to public health pharmaceutical products or to require actions of another country which interfere with a country's access to such products.
Cosponsors
Members who signed on, in the order they did.
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| Senate | Finance Committee | Referred Oct 8, 2004 |
Actions 3
Everything that happened, newest first.
- Oct 8, 2004Introduced in Senate
- Oct 8, 2004Sponsor introductory remarks on measure. (CR S10847-10848)
- Oct 8, 2004Read twice and referred to the Committee on Finance. (text of measure as introduced: CR S10848)
In the Congressional Record 1
Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.
Titles 1
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- A bill to provide that no funds may be expended by the United States Trade Representative to negotiate data exclusivity provisions for certain pharmaceutical products.
Subjects
Assigned by the Library of Congress. Policy area: Foreign Trade and International Finance.
- AIDS (Disease)
- Clinical trials
- Commerce
- Drug approvals
- Drug industry
- Drugs
- Emergency Management
- Emergency medicine
- Epidemics
- Foreign Trade and International Finance
- Generic drugs
- Government Operations and Politics
- Health
- Human immunodeficiency viruses
- International Affairs
- Malaria
- Office of the U.S. Trade Representative
- Trade agreements
- Trade negotiations
- Tuberculosis
Text 1
Each version as it was printed, newest first.
- Oct 8, 2004Introduced in Senate
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.